Keros Therapeutics

KROS · NASDAQ

$11.40+$0.34 (+3.07%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.06

KROS analyst rating

BuyConsensus of 5 analysts over the last 12 months. 60% rate it a buy.

Strong buy0
Buy3
Hold2
Underperform0
Sell0

12-month price target · 7 analysts

Average $20.20 (+77.2% upside)

Low: $16.16
Now: $11.40
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

KROS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Aug 4, 2026	Maintains	Overweight	$20.00 → $18.00	29%
Leerink Partners	Aug 4, 2026	Maintains	Outperform	$30.00 → $23.00	—
Wells Fargo	Mar 5, 2026	Maintains	Overweight	$23.00 → $20.00	29%
B of A Securities	Nov 28, 2025	Maintains	Neutral	$18.00 → $19.00	64%
Oppenheimer	Nov 12, 2025	Maintains	Outperform	$23.00 → $27.00	45%
Wells Fargo	Nov 11, 2025	Maintains	Overweight	$26.00 → $23.00	29%
Wedbush	Nov 6, 2025	Maintains	Neutral	$15.00 → $16.00	40%

The case for and against

Updated Apr 28, 2026

Bull case

Keros Therapeutics is a promising biopharmaceutical company primarily focused on developing novel therapies for various disorders linked to growth factor-beta proteins. With potential success in ongoing trials for elritercept and Luspatercept's recent FDA and EMA approvals for similar indications, there is a strong possibility for positive clinical outcomes. However, risks include potential failures in clinical, regulatory, manufacturing, and commercial aspects, and the need for additional capital to support future developments.

Bear case

Keros Therapeutics is a biopharmaceutical company with a strong focus on developing novel treatments for hematological, pulmonary, and cardiovascular disorders. While their lead product KER-050 shows potential for treating cytopenias in patients with MDS and myelofibrosis, its efficacy still needs to be proven in clinical trials. Additionally, while the partnership with Takeda for elritercept is promising, it has yet to generate significant revenue for the company. This, coupled with the lack of current earnings and high clinical development costs, indicates a high risk for investors.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.